Q-omics provides the consensus-scored DYNLL1P6 profile across patient tissues and cancer cell-line models. DYNLL1P6 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DYNLL1P6 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, DYNLL1P6 RNA expression shows 5,761 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where DYNLL1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DYNLL1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DYNLL1P6 survival associations across molecular data types. DYNLL1P6 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DYNLL1P6 RNA expression–survival associations across cancer types. High DYNLL1P6 expression shows unfavorable associations in KIRC, KICH, UCS, LIHC and COAD, but favorable associations in OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DYNLL1P6 RNA expression.
This table summarizes DYNLL1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DYNLL1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DYNLL1P6 shows higher tumor expression in KIRC, BLCA, BRCA and STAD. The KIRC box plot shows higher DYNLL1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.073, t-test p = .003).
This table shows molecular features associated with DYNLL1P6 in patient tissues and cancer cell lines. In patient samples, DYNLL1P6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
